News
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
— Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity
— Dosing of MAD stage has been initiated; first results expected for late summer 2023
selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments of T-cell mediated autoimmune diseases, today announced excellent initial safety results of the single ascending dose (SAD) stage in the Phase 1b trial of its drug candidate si-544 in atopic dermatitis patients. si-544 is a selectivity-optimized peptide blocking the ion channel Kv1.3.
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
– First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia. Read more…
Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001
– Addressing high unmet medical need in locally advanced soft tissue sarcoma
– Targeted tumor treatment independent of specific molecular targets or tumor subtypes
Thermosome, a drug development company specializing in targeted tumor therapies, today announced that the first patient has been dosed in April 2023 in the ongoing Phase 1 trial of its lead program THE001. Additional patients will be enrolled following a 6-week monitoring period that includes two treatment cycles.
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the appointment of Dr. Rachel Abbott as Chief Executive Officer (CEO). Rachel steps up from her current role as Pan Cancer T’s Chief Scientific Officer (CSO), succeeding Katrien Reynders-Frederix who has served as CEO since the company’s inception.